The present invention relates to a composition comprising cannabidiol and at least two excipients, wherein at least one excipient is a lipid excipient and wherein at least one excipient is a hydrophilic excipient, and wherein the lipid excipient is present in an amount equal to or lower than 20% of the total weight of the composition; the invention also relates to the preparation process of the composition and to pharmaceutical or nutraceutical formulations containing it.

Disclosed are compositions and methods for the treatment of pain and/or inflammation. In certain embodiments, the disclosed compositions and methods have anti-inflammatory activity. In some embodiments, the disclosed compositions and methods have analgesic activity. The present disclosure provides that two non-steroidal anti-inflammatory agents, as for example, 2-(4-isobutylphenyl)propanoic acid (ibuprofen), acetylsalicylic acid (aspirin), a muscle relaxant, and cannabidiol (CBD) can be used in combination in a topical formulation as an effective analgesic and/or anti-inflammatory agent.

A method of treating or alleviating symptoms of disease, disorder or condition associated body wasting in a subject, including disease, disorder or condition associated body wasting in the subject, the disorder or condition identified based on initial measures of body mass, body mass index, or a bloodstream concentration of a substance, orally administering to said subject an amount of curcumin over a period of time effective treat or alleviate the disease, disorder or condition associated body wasting, diminishing or reversing the body wasting in the subject, and assessing efficacy of treating or alleviating symptoms of the disease, disorder or condition associated with body wasting by comparing final measures of body mass, body mass index, or a bloodstream concentration of a substance after the treatment period time to the initial measures of body mass, body mass index, or bloodstream concentration of the substance.

Systems and methods of forming electrospun structures including pharmaceuticals are disclosed. An electrospun structure can include one or more polymers electrospun from a polymer solution comprising a pharmaceutical such that the pharmaceutical is dispersed throughout the one or more electrospun polymers. The pharmaceutical can include a cannabinoid, a phytocannabinoid, a terpene produced by a Cannabis plant, or a combination thereof. The one or more electrospun polymer are configured to degrade over a predetermined time period to deliver the pharmaceutical over the predetermined time period.

Provided is a transdermal drug delivery system comprising cannabidiol, or a cannabidiol salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.

The present disclosure relates to the transdermal administration of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).

An electronic device includes a mouthpiece, a bladder, and a mesh assembly having a mesh material and a piezoelectric material. The mesh material is in contact with a liquid of the bladder. The mouthpiece, the bladder, and the mesh assembly are located in-line along a longitudinal axis of the device between opposite longitudinal ends of the device, with the mesh assembly extending between and separating the mouthpiece and the bladder. A liquid-filled cartridge also is disclosed for use with an electronic device for delivery of a substance into a body through respiration includes a liquid container; and a liquid contained within the container for aerosolizing and inhaling by a person using the electronic device. The liquid includes a plurality of nanoparticles in a nanoemulsion, the nanoparticles including the encapsulation of the substance to be delivered into the body through respiration. The nanoemulsion preferably is produced using a microfluidizing machine.

A cosmetic and pharmaceutical preparation for topical use contains from about 0.00001 wt.-% to about 20 wt.-%, of one or more alkaloids of Mitragyna speciosa and from about 0.00001 wt.-% to about 20 wt.-% of one or more cannabinoids of Cannabis indica or Cannabis sativa. The preparation is intended for use in preventing and/or treating skin and mucosal disorders and conditions.

Compositions and methods are disclosed directed to nanoformulations of cannabidiol.

The invention provides compositions containing a cannabinoid (e.g., cannabidiol) and optionally one or more bioactive agents for the treatment and/or prevention of diseases including ophthalmic diseases or conditions, dermatologic conditions, infections, inflammatory diseases, and vision disorders. The invention also provides compositions and methods of preparing the compositions containing cannabinoids for cosmetic dermatologic applications and a pharmaceutical eluting contact lens. Furthermore, the invention provides delivery vehicles including lipid-polymer particles and methods of preparing the lipid-polymer particles to deliver the compositions to a subject.